Literature DB >> 7779423

Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies.

S E Cowen1, M C Bibby, J A Double.   

Abstract

Numerous vaso-active agents can affect vasculature in experimental solid tumours growing subcutaneously (s.c.), but these models are unlikely to reflect the vasculature of metastatic disease in man. The present study describes a murine orthotopic colon tumour which metastasises to the liver. Morphology and vascular pattern of caecal tumours is similar to s.c. tumours. Vascular occlusion caused by intravenous (i.v.) noradrenaline (NA) (160 micrograms kg-1) and hydralazine (HDZ) (10 mgkg-1) was 32% and 59% respectively for the caecal tumours compared with 35% and 78% for s.c. tumours. Significant morphological differences were seen between liver metastases and systemic deposits produced by i.v. inoculation of tumour cells. Liver metastases following orthotopic transplantation contained functional vasculature but no significant occlusion was seen with NA or HDZ. The vascular development and morphological appearance of secondary disease resulting from orthotopic implantation suggests that this would be a useful model for the study of agents that act either by vascular or anti-angiogenic mechanism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779423     DOI: 10.3109/02841869509093989

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  13 in total

Review 1.  Current methods for assaying angiogenesis in vitro and in vivo.

Authors:  Carolyn A Staton; Stephen M Stribbling; Simon Tazzyman; Russell Hughes; Nicola J Brown; Claire E Lewis
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

2.  An ultra-metastatic model of human colon cancer in nude mice.

Authors:  F X Sun; A R Sasson; P Jiang; Z An; R Gamagami; L Li; A R Moossa; R M Hoffman
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

3.  Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection.

Authors:  Z An; P Jiang; X Wang; A R Moossa; R M Hoffman
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

4.  Whole-body and intravital optical imaging of angiogenesis in orthotopically implanted tumors.

Authors:  M Yang; E Baranov; X M Li; J W Wang; P Jiang; L Li; A R Moossa; S Penman; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

5.  Hypoxia in models of lung cancer: implications for targeted therapeutics.

Authors:  Edward E Graves; Marta Vilalta; Ivana K Cecic; Janine T Erler; Phuoc T Tran; Dean Felsher; Leanne Sayles; Alejandro Sweet-Cordero; Quynh-Thu Le; Amato J Giaccia
Journal:  Clin Cancer Res       Date:  2010-09-21       Impact factor: 12.531

Review 6.  Animal models for exploring the pharmacokinetics of breast cancer therapies.

Authors:  Omar M Rashid; Kazuaki Takabe
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-11-21       Impact factor: 4.481

7.  Minimal liver resection strongly stimulates the growth of human colon cancer in the liver of nude mice.

Authors:  B Rashidi; Z An; F X Sun; A Sasson; R Gamagammi; A R Moossa; R M Hoffman
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

Review 8.  A critical review of lipid-based nanoparticles for taxane delivery.

Authors:  Lan Feng; Russell J Mumper
Journal:  Cancer Lett       Date:  2012-07-13       Impact factor: 8.679

9.  Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model.

Authors:  Jessica Kalra; Jennifer Baker; Justin Song; Alastair Kyle; Andrew Minchinton; Marcel Bally
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

10.  Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model.

Authors:  S E Holwell; B T Hill; M C Bibby
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.